Enoxaparin Superior to Unfractionated Heparin for STEMI at 12 months Follow Up: ExTRACT-TIMI 25 Trial
/
RSS Feed
David Morrow
REFERENCE: Abstract 1027, Clinical Trial Update I, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
DAVID MORROW, Brigham and Women’s Hospital, Boston
Further data to support the use of enoxaparin has come out of the latest update from the ExTRACT-TIMI 25 study. It shows at 12 months follow up, that the benefits of enoxaparin are durable and still superior to unfractionated heparin for patients with ST elevation myocardial infarction undergoing fibrinolytic therapy. Sarah Maxwell interviewed David Morrow at the Vienna meeting.
DAVID MORROW, Brigham and Women’s Hospital, Boston
Further data to support the use of enoxaparin has come out of the latest update from the ExTRACT-TIMI 25 study. It shows at 12 months follow up, that the benefits of enoxaparin are durable and still superior to unfractionated heparin for patients with ST elevation myocardial infarction undergoing fibrinolytic therapy. Sarah Maxwell interviewed David Morrow at the Vienna meeting.
